Iovance Biotherapeutics surges after historic cell therapy approval
Arctic Aurora LifeScience and Biotech Select holding Iovance appreciated 94% year to date including 72% after the approval of their cell therapy treatment in advanced skin cancer.
When a tumor develops, our immune system recognizes and attacks it. There is a select group of immune cells that are able to eliminate tumor cells. These cells are unique to each patient and each tumor. However, as cancer progresses, it evades these specific cells and they become depleted.
The core idea of Iovance's new therapy is to take these natural cancer-fighting immune cells from the patient, re-invigorate and expand them, and give them back to the patient so they can more effectively eliminate tumor cells.
On February 16, the FDA approved the first such drug, AMTAGVI, for advanced skin cancer, or melanoma, a disease that kills 8,000 people each year in the U.S. alone. The approval is based on a Phase 3 trial in which the therapy produced deep and durable responses in patients who had no other options. This makes AMTAGVI the first approved individualized cell therapy for solid tumors. AMTAGVI is also being tested in several other tumors, including cervical and lung cancer. Based on this positive news, sales of the drug are expected to reach USD 900 million by the end of the decade.
Latest news
Arctic Asset Management - Biotech hitting the news
This morning, Ulrica Slåne Bjerke, portfolio manager and CIO for our healthcare funds Arctic Aurora LifeScience and Biotech Select, was invited to Dagens Industri’s TV Börsmorgon. She commented on topics currently in focus regarding the sector, obesity stocks Novo and Lilly, falling interest rates positive for biotech, Novavax share price soaring as well as some Swedish med tech companies having an uphill day.
Arctic Asset Management - Arctic Midt i Måneden - Hvordan bruker proffene informasjonsflyten i rapporteringssesongen - del 2
I studio har Albert Collett fått besøk av aksjeforvalter, Alexander Larstedt Lager, og renteforvalter, Vegard Kjølhamar som forteller hvilken informasjon de vektlegger og hvordan de bruker denne inn i investeringsbeslutningene.
Arctic Asset Management - Markedskommentar April 2024
Oslo Børs var sterkeste aksjemarked i Norden i april hjulpet av oppgang i råvarepriser, god fart i shipping og en svakere krone. Den nordiske Vinx-indeksen (i NOK) leverte også positiv avkastning. Amerikanske S&P 500 og verdensindeksen falt tilbake med motvind i økte amerikanske langrenter. Flere av de store amerikanske tech-selskapene leverte Q1-resultater bedre enn konsensus forventning og har dermed drevet mye av kursoppgangen mot slutten av måneden.
Arctic Asset Management - Obesity companies continue to deliver superior growth in the first quarter of 2024
Both Novo Nordisk and Eli Lilly have reported quarterly results in recent days and continue to show growth rates well above their peers in the pharmaceutical industry.
Arctic Asset Management - Arctic Midt i Måneden - Hvordan bruker proffene informasjonsflyten i rapporteringssesongen
I denne episoden av Arctic Midt i Måneden er aksjeforvalter Ole Dahl og analytiker Arild Huitfeldt på besøk i studio hos Albert Collett, der de gir innblikk i hvordan de jobber for å oppnå best mulig avkastning for investorene.
Arctic Asset Management - Biopharma is finally improving depression treatment outcomes and providing more options to patients
On Tuesday April 16, psychiatry specialists, and Arctic Aurora LifeScience and Arctic Aurora Biotech Select holding, Intra-Cellular Therapies rallied nearly 25% on positive Phase 3 clinical trial depression results. The news adds to the list of good news in the treatment landscape for Major Depressive Disorder or MDD, colloquially known as depression.